Swiss Drug Giant Drops $1.1 Billion On Quiet Boston Biotech Bet
Novartis agreed to buy Myricx Bio for up to $1.5 billion, adding a novel ADC payload platform and underscoring the Boston‑area connections between small biotech and big pharma. The deal could reshape local hiring and partnership flows as programs move toward clinical development.












